No abstract

Four ruthenium(II) complexes with the formula [Ru(eta(5)-C(5)H(5))(PP)L][CF(3)SO (3)], being (PP = two triphenylphosphine molecules), L = 1-benzylimidazole, 1; (PP = two triphenylphosphine molecules), L = 2,2'bipyridine, 2; (PP = two triphenylphosphine molecules), L = 4-Methylpyridine, 3; (PP = 1,2-bis(diphenylphosphine) ethane), L = 4-Methylpyridine, 4, were prepared, in view to evaluate their potentialities as antitumor agents. The compounds were completely characterized by NMR spectroscopy and their crystal and molecular structures were determined by X-ray diffraction. Electrochemical studies were carried out giving for all the compounds quasi-reversible processes. The images obtained by atomic force microscopy (AFM) suggest interaction with pBR322 plasmid DNA. Measurements of the viscosity of solutions of free DNA and DNA incubated with different concentrations of the compounds confirmed this interaction. The cytotoxicity of compounds 1234 was much higher than that of cisplatin against human leukemia cancer cells (HL-60 cells). IC (50) values for all the compounds are in the range of submicromolar amounts. Apoptotic death percentage was also studied resulting similar than that of cisplatin. (C)

Research on the field of metal complexes for the treatment of cancer diseases has attracted increasing interest due to the urgency in finding more efficient and selective treatments. Owing to their wide structural diversity, organometallic complexes appear as potential alternatives to the design of new anticancer candidates. Herein, we review recent progress in our work toward the development of new drugs based on Ru(II)- and Fe(II)-cyclopentadienyl scaffolds. Their design and chemical properties are reviewed and correlated with their biological effects, in particular the key role that coligands play in the overall behavior of the complex.

Borohydrido-halflanthanidocene/dialkylmagnesium combinations are found to be powerful catalytic systems for the chain transfer polymerization of isoprene and its copolymerization with styrene. A behavior close to a lanthanide catalyzed polyisoprene chain growth on magnesium is reported. Transmetalation is further shown to occur in the course of the statistical copolymerization of isoprene and styrene. For the same monomer feed, the amount of styrene inserted in the copolymer can be increased by a factor 3 using 10 equiv. dialkylmagnesium versus 1 in the range of our experimental conditions. Chain transfer in the course of a metal catalyzed statistical copolymerization may thus be viewed as a new and original way for the control of the composition of a copolymer.

A lanthanide half-sandwich complex and a ansa lanthanidocene have been assessed for isoprene-styrene chain shuttling copolymerization with n-butylethylmagnesium (BEM). In the presence of 1 equiv BEM, a fully amorphous multiblock microstructure of soft and hard segments is achieved. The microstructure consists of poly(isoprene-co-styrene) blocks, with hard blocks rich in styrene and soft blocks rich in isoprene. The composition of the blocks and the resulting glass transition temperatures (Tg ) can be easily modified by changing the feed and/or the relative amount of the catalysts, highlighting a new class of thermoplastic elastomers (TPEs) with tunable transition temperatures. The materials self-organize into nanostructures in the solid state.

A set of structurally related Ru(η(5)-C5H5) complexes with bidentate N,N'-heteroaromatic ligands have been evaluated as prospective metallodrugs, with focus on exploring the uptake and cell death mechanisms and potential cellular targets. We have extended these studies to examine the potential of these complexes to target cancer cell metabolism, the energetic-related phenotype of cancer cells. The observations that these complexes can enter cells, probably facilitated by binding to plasma transferrin, and can be retained preferentially at the membranes prompted us to explore possible membrane targets involved in cancer cell metabolism. Most malignant tumors present the Warburg effect, which consists in increasing glycolytic rates with production of lactate, even in the presence of oxygen. The reliance of glycolytic cancer cells on trans-plasma-membrane electron transport (TPMET) systems for their continued survival raises the question of their appropriateness as a target for anticancer drug development strategies. Considering the interesting findings that some anticancer drugs in clinical use are cytotoxic even without entering cells and can inhibit TPMET activity, we investigated whether redox enzyme modulation could be a potential mechanism of action of antitumor ruthenium complexes. The results from this study indicated that ruthenium complexes can inhibit lactate production and TPMET activity in a way dependent on the cancer cell aggressiveness and the concentration of the complex. Combination approaches that target cell metabolism (glycolytic inhibitors) as well as proliferation are needed to successfully cure cancer. This study supports the potential use of some of these ruthenium complexes as adjuvants of glycolytic inhibitors in the treatment of aggressive cancers.

New ruthenium methyl-cyclopentadienyl compounds bearing bipyridine derivatives with the general formula [Ru(η-MeCp)(PPh)(4,4'-R-2,2'-bpy)] (Ru1, R = H; Ru2, R = CH; and Ru3, R = CHOH) have been synthesized and characterized by spectroscopic and analytical techniques. Ru1 crystallized in the monoclinic P2/ c, Ru2 in the triclinic P1̅, and Ru3 in the monoclinic P2/ n space group. In all molecular structures, the ruthenium center adopts a "piano stool" distribution. Density functional theory calculations were performed for all complexes, and the results support spectroscopic data. Ru1 and Ru3 were poor substrates of the main multidrug resistance human pumps, ABCB1, ABCG2, ABCC1, and ABCC2, while Ru2 displayed inhibitory properties of ABCC1 and ABCC2 pumps. Importantly, all compounds displayed a very high cytotoxic profile for ovarian cancer cells (sensitive and resistant) that was much more pronounced than that observed with cisplatin, making them very promising anticancer agents.

A series of lanthanum and neodymium complexes comprising the half-lanthanidocenes Cp*La(BH 4 ) 2 (THF) 2 (Cp* ¼ C 5 Me 5 ) (1) and Cp*Nd(BH 4 ) 2 (THF) 2 (2), the trisborohydrides La(BH 4 ) 3 (THF) 3 (3) and Nd(BH 4 ) 3 (THF) 3 (4), the trichlorides LaCl 3 (THF) 3 (5) and NdCl 3 (THF) 3 (6), the triisopropoxides La(O i Pr) 3 (7) and Nd(O i Pr) 3 (8), and the triaryloxide Nd(OC 6 H 3 -t Bu 2 -2,6) 3 (9) has been assessed for the chain transfer polymerization of isoprene. A transmetalation process is occurring efficiently with the borohydride complexes in the presence of magnesium dialkyl. A gradual decrease of the 1,4-trans stereoselectivity of the reaction is observed at the benefit of 3,4-selectivity with increasing quantities of magnesium dialkyl. This can be at least partially attributed to the growth of 3,4 polyisoprene units onto the magnesium atom. By combining dialkylmagnesium and trialkylaluminum, a 1,4-trans stereospecific reversible coordinative chain transfer polymerization of isoprene is reached using the half-lanthanocene Cp*La(BH 4 ) 2 (THF) 2 . V C 2010 Wiley Periodicals, Inc. J Polym Sci Part A: Polym Chem 48: [4640][4641][4642][4643][4644][4645][4646][4647] 2010